Phosphoinositide 3-kinase δ inhibitor suppresses interleukin-17 expression in a murine asthma model

European Respiratory Journal

Volumn 36, Issue 6, 2010, Pages 1448-1459

  Park, S J ^a   Lee, K S ^a   Kim, S R ^a   Min, K H ^a   Moon, H ^a   Lee, M H ^a   Chung, C R ^a   Han, H J ^a   Puri, K D ^b   Lee, Y C ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Calistoga Pharmaceuticals   (United States)

Author keywords

Asthma; Interleukin 17; Nuclear factor B; P110 ; Phosphoinositide 3 kinase

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; BAY 117085; CHEMOATTRACTANT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; OVALBUMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PROTEIN KINASE B; UNCLASSIFIED DRUG;

AIRWAY; ALLERGIC DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE MODEL; ENZYME ACTIVITY; ENZYME INHIBITION; EOSINOPHIL; FEMALE; IMMUNOREGULATION; INFLAMMATORY CELL; LUNG CLEARANCE; LYMPHOCYTIC INFILTRATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RESPIRATORY TRACT INFLAMMATION; SIGNAL TRANSDUCTION;

ADENINE; ANIMALS; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOTACTIC FACTORS; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; EOSINOPHILS; FEMALE; INTERLEUKIN-17; INTERLEUKIN-4; INTERLEUKIN-5; LUNG; LYMPHOCYTES; MICE; MICE, INBRED C57BL; NEUTROPHILS; NF-KAPPA B; NITRILES; QUINAZOLINES; SULFONES;

EID: 78349304262     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00106609     Document Type: Article

References (38)

1. Bousquet J, Jeffery PK, Busse WW, et al. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161: 1720-1745.
2. Park SJ, Min KH, Lee YC. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma. Respirology 2008; 13: 764-771.
3. Rommel C, Camps M, Ji H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 2007; 7: 191-201.
4. Kwak YG, Song CH, Yi HK, et al. Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest 2003; 111: 1083-1092.
5. Chantry D, Vojtek A, Kashishian A, et al. p110δ, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997; 272: 19236-19241.
6. Sadhu C, Masinovsky B, Dick K, et al. Essential role of phosphoinositide 3-kinase δ in neutrophil directional movement. J Immunol 2003; 170: 2647-2654.
7. Puri KD, Doggett TA, Douangpanya J, et al. Mechanisms and implications of phosphoinositide 3-kinase δ in promoting neutrophil trafficking into inflamed tissue. Blood 2004; 103: 3448-3456.
8. Lee KS, Lee HK, Hayflick JS, et al. Inhibition of phosphoinositide 3- kinase d attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J 2006; 20: 455-465.
9. Lee KS, Park SJ, Kim SR, et al. Phosphoinositide 3-kinase-δ inhibitor reduces vascular permeability in a murine model of asthma. J Allergy Clin Immunol 2006; 118: 403-409.
10. Pappu BP, Angkasekwinai P, Dong C. Regulatory mechanisms of helper T cell differentiation: new lessons learned from interleukin 17 family cytokines. Pharmacol Ther 2008; 117: 374-384.
11. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6: 1133-1141.
12. Kim SR, Lee KS, Park SJ, et al. PTEN down-regulates IL-17 expression in a murine model of toluene diisocyanate-induced airway disease. J Immunol 2007; 179: 6820-6829.
13. Hellings PW, Kasran A, Liu Z, et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol 2003; 28: 42-50.
14. Barczyk A, Pierzchala W, Sozanska E. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir Med 2003; 97: 726-733.
15. Molet S, Hamid Q, Davoine F, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108: 430-438.
16. Wong CK, Ho CY, Ko FW, et al. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma. Clin Exp Immunol 2001; 125: 177-183.
17. Sun YC, Zhou QT, Yao WZ. Sputum interleukin-17 is increased and associated with airway neutrophilia in patients with severe asthma. Chin Med J 2005; 118: 953-956.
18. Bullens DM, Truyen E, Coteur L, et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res 2006; 7: 135.
19. Kim KW, Cho ML, Park MK, et al. Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor κB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther 2005; 7: R139-R148.
20. + T cells via down-regulation of PI3K/Akt and NF-kB. Immunol Lett 2007; 108: 88-96.
21. Cho ML, Kang JW, Moon YM, et al. STAT3 and NF-κB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol 2006; 176: 5652-5661.
22. Hennessy BT, Smith DL, Ram PT, et al. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4: 988-1004.
23. Dhand R, Hara K, Hiles I, et al. PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J 1994; 13: 511-521.
24. Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 2003; 3: 426-434. (Pubitemid 36908947)
25. Ali K, Bilancio A, Thomas M, et al. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature 2004; 431: 1007-1011.
26. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-476.
27. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
28. Hoshino H, Lötvall J, Skoogh BE, et al. Neutrophil recruitment by interleukin-17 into rat airways in vivo. Role of tachykinins. Am J Respir Crit Care Med 1999; 159: 1423-1428.
29. Laan M, Cui ZH, Hoshino H, et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999; 162: 2347-2352.
30. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001; 194: 519-527.
31. Larché M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003; 111: 450-463.
32. Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160: 1532-1539.
33. Woodruff PG, Khashayar R, Lazarus SC, et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 2001; 108: 753-758.
34. Schnyder-Candrian S, Togbe D, Couillin I, et al. Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 2006; 203: 2715-2725.
35. Nakae S, Komiyama Y, Nambu A, et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002; 17: 375-387.
36. Kumar A, Takada Y, Boriek AM, et al. Nuclear factor-κB: its role in health and disease. J Mol Med 2004; 82: 434-448.
37. Uhlig U, Fehrenbach H, Lachmann RA, et al. Phosphoinositide 3- OH kinase inhibition prevents ventilation-induced lung cell activation. Am J Respir Crit Care Med 2004; 169: 201-208.
38. Bai D, Ueno L, Vogt PK. Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt. Int J Cancer 2009; 125: 2863-2870.